In 2013, the World Health Assembly endorsed a plan that calls for the ultimate withdrawal of
oral polio vaccines (OPV) from all immunization programs globally. The withdrawal would …

Background Novel oral poliovirus vaccine type 2 (nOPV2) was used to control an outbreak
of type 2 circulating vaccine derived poliovirus (cVDPV2) in Tajikistan, in 2021. We …

Summary Background Pakistan and Afghanistan are two of the three remaining countries yet
to interrupt wild-type poliovirus transmission. The increasing incidence of poliomyelitis in …

Background A high-potency monovalent oral type 1 poliovirus vaccine (mOPV1) was
developed in 2005 to tackle persistent poliovirus transmission in the last remaining infected …

Background Fractional-dose administration of inactivated poliovirus vaccine (fIPV) could
increase IPV affordability and stretch limited supplies. We assessed immune responses …

With the COVID-19 pandemic abating, the only remaining Public Health Emergency of
International Concern is polio [1]. Remarkable progress has been made in reducing the …

For the final stages in the eradication of poliovirus type 1 (P1), the World Health
Organization advocates the selective use of monovalent type 1 oral poliovirus vaccine …

Background. Mucosal immunity induced by oral poliovirus vaccine (OPV) is imperfect and
potentially allows immunized individuals to participate in asymptomatic wild-type poliovirus …

Background A recent WHO review concluded that live BCG and measles vaccine (MV) may
have beneficial non-specific effects (NSEs) reducing mortality from non-targeted diseases …

Background. Routine vaccines may have nonspecific effects on mortality. An observational
study found that OPV given at birth (OPV0) was associated with increased male infant …